Stories from people navigating msi-h — diagnosis, treatment, caregiving, and the ordinary days in between.
2 stories
Oncology
Accelerated approval makes dostarlimab an initial option for previously untreated stage II or III MSI-H/dMMR rectal cancer, with the possibility of avoiding chemotherapy, radiation and surgery.
Rayan Salih · October 26, 2026 · 6 min
Oncology
FDA accelerated approval covers selected previously untreated adults with MSI-H or dMMR locally advanced rectal cancer, allowing standard chemoradiation and surgery to be deferred when a complete clinical response is sustained.
Rayan Salih · 7 min read
Other conditions
One story a day
One health journey each morning — no advice, no alarm, just company for the road.